The <scp> <i>GBA1</i> </scp> p. <scp>E427K</scp> (p. <scp>E388K</scp> ) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis

BACKGROUND: Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear. OBJECTIVE: The aim was to determine whether the GBA1 p.E427K variant is associated with risk of synucleinopathies. METHODS: We performed a meta-analysis of case-control studies reporting the frequency of GBA1 p.E427K (p.E388K) in PD and related synucleinopathies. Data were obtained from published studies, open-access resources, and large cohorts, including in-house datasets. Odds ratios (OR) were calculated for each cohort and pooled using a random-effects model. RESULTS: Across 67,221 patients and 123,832 controls, GBA1 p.E427K was associated with increased disease risk (pooled OR = 1.94, 95% confidence interval 1.33-2.84, P = 0.0007). Enzymatic data showed reduced glucocerebrosidase activity in carriers. CONCLUSIONS: The GBA1 p.E427K variant is a risk factor for synucleinopathies and should be considered in genetic studies and clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Authors

Institutions

Publication Details

Journal
Movement Disorders
Published
2026-05-22
DOI
https://doi.org/10.1002/mds.70367
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The GBA1 p. E427K (p. E388K ) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis

Farnaz Asayesh, Алла Тимофеева, Orly Goldstein, Oury Monchi et al.
Movement Disorders
Lysosomal Storage Disorders Research
article

The GBA1 p. E427K (p. E388K ) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis

Farnaz Asayesh, Алла Тимофеева, Orly Goldstein, Oury Monchi, James C. Beck, Sitki Cem Parlar, Mandy Radefeldt, Christine Klein, Lior Greenbaum, Christian Beetz, Leah V. Chifamba, Irina Miliukhina, Sofya Pchelina, Anton Emelyanov, Y Dauvilliers, Allison A. Dilliott, Peter Bauer, Sharon Hassin‐Baer, Lang Liu, Konstantin Senkevich, Eric Yu, Jamil Ahmad, Jennifer A. Ruskey, Cheryl Waters, Roy N. Alcalay, ROPAD Study Group, Ziv Gan‐Or, Nicolas Dupré, Emma N. Somerville, Meron Teferra
article en

Abstract

BACKGROUND: Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear. OBJECTIVE: The aim was to determine whether the GBA1 p.E427K variant is associated with risk of synucleinopathies. METHODS: We performed a meta-analysis of case-control studies reporting the frequency of GBA1 p.E427K (p.E388K) in PD and related synucleinopathies. Data were obtained from published studies, open-access resources, and large cohorts, including in-house datasets. Odds ratios (OR) were calculated for each cohort and pooled using a random-effects model. RESULTS: Across 67,221 patients and 123,832 controls, GBA1 p.E427K was associated with increased disease risk (pooled OR = 1.94, 95% confidence interval 1.33-2.84, P = 0.0007). Enzymatic data showed reduced glucocerebrosidase activity in carriers. CONCLUSIONS: The GBA1 p.E427K variant is a risk factor for synucleinopathies and should be considered in genetic studies and clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Movement Disorders
Montreal Neurological Institute and Hospital (CA), Tel Aviv University (IL), Columbia University Irving Medical Center (US), First Pavlov State Medical University of St. Petersburg (RU), Tel Aviv Sourasky Medical Center (IL), Sheba Medical Center (IL), McGill University Health Centre (CA), Centre Hospitalier Universitaire de Montpellier (FR), Institute of the Human Brain (RU), Hôpital Gui de Chauliac (FR), University Hospital Schleswig-Holstein (DE), Institut Universitaire de Gériatrie de Montréal (CA), Centogene (Germany) (DE), Parkinson's Foundation (US), Université Laval (CA), McGill University (CA), Université de Montréal (CA), Columbia University (US), University of Lübeck (DE)
Partnerships for the goals
Openalex Percentile: Top 5%
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.